Treatment Resistant Depression: Causes, Options and What Actually Works

Written by Aisha Saleem, Pharmacist & Health Writer at PharmaHealths.com

Last Updated: July 2026

Depression responds well to treatment for most people. A course of antidepressants, some psychological support, and time, and many patients do find meaningful relief. But for a significant number, that straightforward path does not deliver enough improvement. Medication after medication, week after week, and the depression simply does not lift to a functional level. If that sounds familiar, there is a clinical term for what you are experiencing, and more importantly, there are structured, evidence-based options beyond a standard healthcare provider approach.

Treatment resistant depression is not a dead end. It is a recognized clinical condition with its own evidence-based treatment pathways, and understanding it fully is the first step toward finding what actually works for you.

What Is Treatment Resistant Depression?

Treatment resistant depression (TRD) is defined as major depressive disorder that fails to respond adequately to at least two different antidepressant medications, each taken at the right dose for a sufficient duration, typically six to eight weeks.

This threshold matters. TRD is not a label for someone who stopped medication early or took too low a dose. It applies when treatment has genuinely been given a fair chance and has not delivered enough relief.

Rush et al. (2006) in the American Journal of Psychiatry reported that the STAR*D trial, one of the most comprehensive real-world studies of depression treatment ever conducted, found that approximately one in three patients did not achieve remission even after four sequential treatment attempts, establishing TRD as a distinct and serious clinical challenge.

TRD does not have a single cause. It develops from several overlapping biological and clinical factors that reduce treatment response.

At the neurobiological level, depression is not simply a serotonin deficiency. Research from the National Institute of Mental Health shows that TRD involves dysregulation across multiple systems, including the glutamate pathway, the HPA axis, inflammatory signaling, and reduced neuroplasticity in key regions such as the prefrontal cortex and hippocampus. Standard antidepressants, which primarily target monoamine pathways, do not address all of these systems.

Misdiagnosis also plays a larger role than often recognized. Conditions such as bipolar disorder, ADHD, thyroid dysfunction, and certain personality disorders can present with depressive features but respond very differently to standard antidepressants. Without identifying these underlying conditions, repeatedly switching medications is unlikely to produce meaningful improvement.

Pharmacogenetic variation also contributes. Some patients metabolize antidepressants too quickly or too slowly at standard doses, leading to suboptimal drug levels even when prescriptions appear correct. This is an increasingly recognized and often underused factor in treatment planning.

Finally, lifestyle and environmental factors such as chronic stress, poor sleep, regular alcohol use, and nutritional deficiencies can sustain neuroinflammation and HPA dysregulation. Without addressing these, medication is working against an unsupportive biological environment.

How Is Treatment Resistant Depression Diagnosed?

TRD is diagnosed through a structured clinical review rather than a single test or scan.

A psychiatrist will assess the full medication history, including how many antidepressants have been tried, at what doses, for how long, and whether there has been any partial response. NICE guidelines recommend ruling out contributing medical conditions such as thyroid disease, vitamin D deficiency, anaemia, and sleep apnoea before confirming a TRD diagnosis, as these can directly impair treatment response and are often overlooked in primary care.

If you have tried two or more antidepressants without adequate relief, asking your doctor for a formal psychiatric referral is entirely appropriate and clinically justified.

What Treatment Options Are Available for TRD?

There is no single correct answer to TRD, which is actually a reason for optimism. Multiple evidence-based pathways exist.

Medication augmentation involves adding a second agent to an existing antidepressant to enhance its effect through a different mechanism. Common options include lithium, atypical antipsychotics such as quetiapine or aripiprazole, and in selected cases thyroid hormone. Bauer et al. (2014) in the International Journal of Neuropsychopharmacology confirmed that lithium augmentation provides meaningful benefit in patients who have not responded to antidepressants alone.

Switching antidepressant class provides a different pharmacological approach, for example from an SSRI to an SNRI, or to an agent such as mirtazapine that works on different receptor pathways. The STAR*D data showed that sequential switching, when done properly, leads to remission in a meaningful proportion of patients.

Psychological therapies also have a strong evidence base as adjuncts. Mindfulness Based Cognitive Therapy is recommended by NICE for recurrent depression. Cuijpers et al. (2014) in JAMA Psychiatry found that combining psychotherapy with antidepressants significantly outperformed medication alone in moderate to severe depression.

Transcranial Magnetic Stimulation (TMS) is a non-invasive outpatient procedure that delivers targeted magnetic pulses to the prefrontal cortex over four to six weeks. It does not require sedation and does not cause systemic side effects. George et al. (2010) in Brain Stimulation reported that active TMS produced significantly higher remission rates compared to sham treatment, with response rates around 50 to 60 percent.

Ketamine and esketamine represent a major development in depression treatment. By targeting NMDA glutamate receptors rather than monoamine pathways, ketamine can produce antidepressant effects within hours to days. Popova et al. (2019) in the New England Journal of Medicine showed that esketamine combined with a new antidepressant was significantly more effective than placebo plus antidepressant in patients with treatment resistant depression. NICE approved esketamine nasal spray in 2022 for adults with TRD who have not responded to at least two antidepressants.

Lifestyle co interventions, particularly aerobic exercise, sleep optimization, and anti-inflammatory dietary patterns, also have meaningful evidence as adjuncts. Kvam et al. (2016) in JAMA Psychiatry demonstrated that exercise has significant antidepressant effects through mechanisms that overlap with pharmacological treatment. These interventions actively support treatment response rather than simply improving general wellbeing.

When Should You Push for a Specialist Referral?

If you have tried two or more antidepressants at the correct dose and duration without adequate relief, a referral to a psychiatrist is clinically warranted rather than continuing repeated prescriptions.

A specialist can provide a more detailed diagnostic review, access to augmentation strategies, and assessment for advanced options such as TMS or esketamine. Early referral improves access to appropriate treatment pathways.

Being persistent about this referral is not an overreaction. It is the correct clinical next step.

Can Treatment Resistant Depression Actually Get Better?

Yes, and the evidence supports this clearly.

The STAR*D trial found that cumulative remission rates approached 67 percent after four sequential treatment steps. This shows that most patients with TRD can achieve meaningful improvement when treatment is systematically adjusted. The best outcomes are seen in patients who access specialist care, address contributing lifestyle factors, and continue beyond initial treatment failure.

TRD requires a different strategy, not a lower expectation.

Conclusion

Treatment resistant depression reflects the need for a more personalized and multi layered approach rather than a lack of treatment options. When standard antidepressants are not enough, combining medication strategies, psychological therapies, and newer interventions can significantly improve outcomes.

With the right evaluation and persistence, meaningful recovery is achievable. The key is not stopping at initial treatment failure but moving toward more targeted and comprehensive care.

FAQs

Q1. How many antidepressants do you need to fail before being diagnosed with TRD?
The clinical threshold is failing at least two antidepressant medications, each taken at an adequate dose for a sufficient duration, typically six to eight weeks. Both medications should ideally be from different drug classes. If that describes your experience, it is worth discussing a formal TRD evaluation with your doctor or psychiatrist.

Q2. Is treatment resistant depression curable?
The word “curable” is complicated in psychiatry, but meaningful and sustained recovery from TRD is absolutely achievable. The STAR*D trial found that the majority of patients with TRD did reach remission when the full range of clinical options was systematically explored. Recovery often requires combining approaches, medication optimization, psychological therapy, and potentially TMS or ketamine, rather than relying on antidepressants alone.

Q3. What is the difference between depression and treatment resistant depression?
Standard depression refers to a major depressive episode that responds to first- or second-line antidepressant treatment. Treatment resistant depression is specifically defined by the failure of at least two adequate antidepressant trials. It does not mean a different illness, it means the same condition requires a more specialist, multi modal approach to treatment.

Q4. Can my doctor treat treatment-resistant depression or do I need a psychiatrist?
A doctor can initiate some augmentation strategies, but TRD generally warrants psychiatric input. A psychiatrist can carry out a fuller diagnostic review, prescribe medications not available in primary care, and assess eligibility for TMS or esketamine. If you have tried two or more antidepressants without adequate relief, asking your doctor for a referral is the appropriate and justified next step.

Q5. Does a partial response to an antidepressant count as treatment resistance?
A partial response, meaning some improvement but not enough to restore normal functioning, sits in a grey area clinically. Many psychiatrists would still consider this inadequate remission if it significantly impacts daily life. This partial picture is worth discussing explicitly with your prescriber, as it may influence whether augmentation or a switch is recommended rather than simply continuing the current medication.

Q6. What lifestyle factors contribute to poor antidepressant response?
Chronic stress, disrupted sleep, regular alcohol use, low physical activity, and a highly processed diet all maintain the neuroinflammation and HPA axis dysregulation that antidepressants are working against. Addressing these factors actively, particularly sleep and exercise, has direct mechanistic relevance to how well medication performs, not just general wellbeing.

Q7. How do I get referred for TMS or ketamine on the NHS?
TMS is available through some NHS specialist centers for patients with confirmed TRD, though access varies significantly by region. Esketamine (Spravato) has NICE approval and is available through NHS England in specific clinical pathways. The starting point in both cases is a referral from your doctor to a psychiatrist or specialist mood disorders service, who can formally assess eligibility and make the appropriate onward referral.

Call to Action

If this article has helped you understand TRD more clearly, I’d encourage you to explore the rest of the mental health section on PharmaHealths.com. I’ve written dedicated guides on TMS therapy versus ketamine, how fast acting antidepressants work through the NMDA pathway, lifestyle interventions that improve antidepressant response, and the top five options available when medication hasn’t delivered enough relief. Each piece is written from a pharmacist’s perspective, evidence based, plainly explained, and designed to help you have better informed conversations with your clinical team.

Disclaimer

This article is written for general informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. Treatment resistant depression is a clinical condition that must be assessed, diagnosed, and managed by a qualified healthcare professional. Always consult your healthcare provider, psychiatrist, or pharmacist before making any changes to your treatment plan. Individual clinical circumstances vary significantly.

References

• Rush AJ et al. (2006). American Journal of Psychiatry, STAR*D trial establishing real world outcomes and treatment resistance rates.

• National Institute of Mental Health⁠, Overview of treatment-resistant depression mechanisms and clinical features.

• Bauer M et al. (2014). International Journal of Neuropsychopharmacology, Evidence supporting lithium augmentation in resistant depression.

• Cuijpers P et al. (2014). JAMA Psychiatry, Combined psychotherapy and medication improve outcomes vs medication alone.

• George MS et al. (2010). Brain Stimulation, Clinical effectiveness of TMS in major depressive disorder.

• Popova V et al. (2019). New England Journal of Medicine, Esketamine efficacy in treatment-resistant depression.

• Kvam S et al. (2016). JAMA Psychiatry, Exercise as an evidence-based treatment for depression.

• National Institute for Health and Care Excellence (NICE) Guideline NG222, Clinical guidelines for depression diagnosis and management.